In the high-stakes arena of oncology, few innovations have captured the pharmaceutical industry’s imagination quite like the bispecific antibody. Specifically, drugs designed to simultaneously target PD-1 (programmed cell death protein 1) and VEGF (vascular endothelial growth factor) have become the "holy grail" for major drugmakers. Following a watershed moment in 2024, when the bispecific drug ivonescimab outperformed Merck’s dominant checkpoint inhibitor Keytruda in a pivotal lung cancer trial, the industry responded with a massive influx of capital, acquisitions, and licensing deals.
However, beneath the veneer of optimism and multi-billion-dollar investments lies a growing undercurrent of skepticism. As companies like BioNTech, Pfizer, and Merck race to replicate the success seen in initial clinical trials, analysts are beginning to question whether the industry is chasing the wrong target. While lung cancer remains the most lucrative market, experts suggest that the biological mechanism of PD-1/VEGF bispecifics may be better suited for other, often overlooked, solid tumors.
A Chronology of the Bispecific Surge
The current frenzy surrounding PD-1/VEGF bispecifics can be traced back to the clinical validation of these dual-action molecules.
- 2024: The Catalyst: The sector experienced a seismic shift when data from a lung cancer trial demonstrated that ivonescimab could outperform Keytruda, the long-standing gold standard in immunotherapy. This result transformed a niche research area into a primary strategic focus for major players.
- Early 2025: The Global Reality Check: In May 2025, further data from Summit Therapeutics’ global phase 3 trials introduced a more nuanced reality. While the drug showed a clear impact on disease progression, the reduction in death risk compared to standard chemotherapy failed to reach statistical significance, highlighting the complexities of moving from regional successes to global patient populations.
- Late 2025 – Early 2026: The Diversification Wave: Recognizing the potential limitations in the lung cancer market, the industry began a strategic pivot. By January 2026, companies like AbbVie had entered into exclusive licensing agreements to develop novel bispecifics for a wider array of solid tumors, signaling an industry-wide effort to hedge bets beyond the lung cancer theater.
Supporting Data: The Lung Cancer Conundrum
The enthusiasm for lung cancer as the primary indication for PD-1/VEGF bispecifics is driven by pure economics. It represents one of the largest addressable markets in oncology, providing a massive return on investment for any drug that secures a dominant position. However, the data supporting these clinical trials has come under scrutiny due to demographic discrepancies.
According to Souro Chowdhury, a senior business analyst at Lifescience Dynamics, the patient populations in initial "success" trials—frequently conducted in China—do not mirror the diverse demographics of Western clinical cohorts. In a recent phase 3 trial for ivonescimab, approximately 93% of the participants were male, with a median age of 64.
"In China, a lot of these trials have enrolled patients who are almost exclusively male and ex or current smokers," Chowdhury observed. "Lung cancer patients in the U.S. may include a more mixed demographic that skews younger, so results may look different."
This demographic gap is not merely academic; it strikes at the heart of the drug’s efficacy. Biological responses to immunotherapy can vary significantly based on age, gender, and smoking history, which are often correlated with the mutation profile of the tumors themselves. Consequently, a drug that appears miraculous in a highly specific, homogeneous cohort may show diminished returns in the heterogeneous, multi-ethnic population of a global phase 3 trial.
Beyond the Lungs: Exploring New Frontiers
If lung cancer is the "low-hanging fruit" that may not yield the expected harvest, where should developers be looking? According to emerging research and expert analysis, the PD-1/VEGF mechanism might be a superior fit for tumors that are more "VEGF-dependent."
Hepatocellular Carcinoma (Liver Cancer)
Liver tumors often exhibit a high reliance on the VEGF protein pathway to maintain their blood supply and promote aggressive growth. Because bispecifics effectively inhibit this pathway while simultaneously stimulating the immune system via PD-1, they could theoretically provide a more profound clinical benefit in the liver than in the lung, where tumor microenvironments differ significantly.
Gastric Cancers
Gastric cancers represent another promising frontier. These tumors often manifest complex signaling pathways where VEGF plays a critical role in progression and metastasis. By blocking both the immunosuppressive PD-1 signal and the pro-angiogenic VEGF signal, researchers believe they could achieve a "synergistic kill" that single-agent therapies cannot replicate.
Diversification as a Risk-Mitigation Strategy
The recent decision by companies like BioNTech to test their bispecific candidates (such as the PD-L1/VEGF-targeting pumitamig) across a spectrum of cancers—including breast, colorectal, and liver—serves a dual purpose.
"There are two ways to look at it," Chowdhury notes. "One could be that they’re looking at the lung evidence as convincing enough that it’s safe now to launch trials in other indications. The other way to look at this is perhaps some of these companies share the skepticism that we’ve been talking about, and so it’s really a way to derisk these large dollar-value acquisitions."
The Implications for the Pharmaceutical Industry
The industry is currently at a crossroads. The billions of dollars already committed to PD-1/VEGF programs create a "sunk cost" momentum that is difficult to reverse. However, the failure to meet statistical significance in key global trials suggests that the "one-size-fits-all" approach to these bispecifics is flawed.
Clinical Implications
Developers must move toward more sophisticated patient stratification. Rather than testing these drugs in broad "all-comer" lung cancer populations, companies may need to identify specific biomarkers that predict which patients will actually respond to the combined inhibition of PD-1 and VEGF. Without this precision, developers risk wasting years and billions of dollars on trials that yield mediocre results.
Strategic Implications
The shift toward diversifying indications is a sign of a maturing market. Investors are beginning to demand that pharmaceutical firms prove the viability of their assets beyond a single, crowded market. For companies like Summit Therapeutics, Akeso, and their global partners, the next 24 months will be critical. The readout of upcoming global trials will likely determine whether the PD-1/VEGF bispecific class will become the new standard of care or if it will be relegated to a secondary status, useful only in highly specific clinical scenarios.
The Investor Perspective
For shareholders, the "bispecific gold rush" is a high-risk, high-reward endeavor. While the initial promise of these drugs remains intact, the "split verdict" of recent trials serves as a warning. The companies that survive this phase will likely be those that demonstrate the clinical agility to pivot away from saturated markets and toward the tumor types where their unique biological mechanisms actually provide a transformative advantage.
Conclusion: A Measured Path Forward
The development of PD-1/VEGF bispecifics is undoubtedly a scientific breakthrough that has fundamentally changed the landscape of cancer research. However, the industry’s narrow focus on the lung cancer market, driven by the lure of massive financial gains, may have blinded developers to the broader potential of these molecules.
As the data continues to mature, the pharmaceutical industry must balance the excitement of innovation with the cold, hard requirements of clinical rigor. If developers can successfully transition from the "all-in-on-lung-cancer" mentality to a more nuanced, site-specific approach to tumor biology, these bispecifics may yet fulfill their promise. If not, the industry risks a series of high-profile disappointments, reinforcing the age-old lesson that in medicine, the most lucrative market is not always the most effective one.
About the Author
